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1. Introduction
Amyloids can have normal biological functions.1-3 How-
ever, amyloidogenic proteins can also form unwanted oli-
gomeric or polymeric aggregates when disturbed from their
native functional states. Such aggregates are associated with
numerous neurodegenerative diseases, such as diabetes type
II,4 Alzheimer (AD), Parkinson, Huntington, and prion (“mad
cow”) diseases, amyotrophic lateral sclerosis, and Down’s
syndrome (DS).5-9 Increasing evidence from studies in
human, transgenic mice, cultured cells, wild type rodent, and
in vitro systems indicates that soluble oligomers of amy-
loidogenic proteins are both responsible for amyloidosis10,11
and are the toxic agent.12-14 Some data suggest that their
ﬁnal large aggregates can also lead to cytotoxicity.15,16
Ordered aggregates can extend into  -strand enriched
ﬁbrils, regardless of their initial native conformational states.
Experimental and computational approaches revealed struc-
tural details of these organizations. Amyloid structural
models were obtained by different methods: spectroscopy,17-23
solid-state NMR (ssNMR),24-29 EPR,30,31 hydrogen/deuterium
exchange,15,27,32 cryo-electron microscopy (cryo-EM) and
electron microscopy (EM),33-36 X-ray ﬁber diffraction and
X-ray diffraction,37-41 and peptide design.42 Apart from a
handful of peptides that were successfully crystallized
providing insight into the ordered amyloid arrangement,43
amyloid structural elucidation has been fraught with dif-
ﬁculties. The insolubility of amyloid ﬁbrils has made
crystallization and solution NMR virtually impossible. Under
these circumstances, ssNMR has been the method of choice
for structural determination, providing insight into the nature
of  -sheet organization.44 ssNMR data of A  segments
coupled with atomistic molecular dynamic simulations have
further been useful in addressing the driving forces for
targeted associations.45,46
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Published on Web 04/19/2010To date, the key question of the mechanism through
which amyloids lead to cytotoxity is still a major
challenge.47-51 As in folding, it is well established that in
amyloid ﬁbrils, nucleation and kinetics depend not only
on inherent features such as the amino acid composition,
sequence, and length, but also on environmental conditions
such as temperature,52 concentration, pH,53 metal ions,
agitation, and enhanced aggregation on the lipid bilayer
surface. At the same time, the self-assembly mechanism that
leads to ordered ﬁbril formation is not fully understood. Open
questions relate to (1) how the monomeric peptides assemble
into oligomers; (2) which segments of a long peptide
constitute the recognition motifs and as such play key roles
in amyloid ﬁbril formation;54 (3) how the  -strands arrange
relative to one another; (4) are there favored organizations
between the  -sheets, and if so (5) what are these and what
are the intermolecular interactions between the layers that
stabilize these; and, ﬁnally, (6) what are the pathways and
the intermediate states that are involved in seed and ﬁbril
formation. These combine to contribute to one of the most
difﬁcult issues that are related to protein aggregation, that
is, aggregate polymorphism; the aggregates can have different
preferred ﬁbril architectures depending on (even slight)
changes in any of these sequence or environmental fac-
tors.
Amyloid   peptide (A  peptide) has served as a paradigm
for studies of amyloid formation and conformations. The full-
length A  peptide has 40-42 residues when cut from its
precursor protein. A  aggregates are observed in brain tissues
of Alzheimer’s patients,55 and it is generally believed that
A  peptide oligomerization is a major mechanism leading
to the neuron-cell death.15 This Review focuses on poly-
morphic A  and other amyloid conformations. It compiles
the conformations of the full-length A 1-42/A 1-40 and its
fragments, and presents amyloid assemblies in terms of the
energy landscape. In addition, it describes how, via confor-
mational selection and population shift as the primary
molecular recognition mechanism,56 monomeric A  states
whose shapes are compatible can assemble into organized
ﬁbril geometries.56-58 Together, this leads to an overview
of the structural variability and the underlying mechanisms
of ﬁbril polymorphism. Understanding the mechanisms and
the range of structural features of the aggregates are of crucial
importance for effective drug design to reduce aggregate
formation.
2. Full-Length -Amyloid and Its Fragments: A
Warehouse of Sequences Prone to Amyloid
Formation and Polymorphism
Most of the information on oligomeric assemblies is
obtained from the full-length  -amyloid peptide A 1-42/
A 1-40.15,25,59-69 The sequence of the human A 1-42 peptide
is 1-DAEFRHDSGY EVHHQKLVFF AEDVGSNKGA
IIGLMVGGVV IA-42. Both the A 1-42 and the shorter
A 1-40 peptides derive from cleavage of the transmembrane
amyloid precursor protein (APP) by  - and γ- secretases.70
There are variations in proteolytic pathways, and thus
different fragments can exist in vivo. The cleavage by R-
and γ- secretases leads to A 17-42 in the so-called “non-
amyloidogenic cleavage”.9,71
Experimentally,53 different full-length A 1-40 conforma-
tions are preferred in the ﬁbril at different pH values. Petkova
et al.72 observed that the distinct ﬁbril morphologies reﬂect
the variation in the molecular structure of A 1-40 at the
protoﬁlament level. As shown in Figure 1A, subtle variations
in ﬁbril growth conditions such as an agitated or quiescent
environment translate into morphological changes of the
dominant amyloid structures; these are captured in the
amyloid seeds and self-propagate.72 In a recent comprehen-
sive study of A 1-40 ﬁbril polymorphism, using cryo-EM
and three-dimensional recognition techniques, Meinhardt et
al.73 have shown that structural persistence and morphological
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same buffer solutions (Figure 1B). However, with two more
residues, the longer A 1-42 peptide displays even larger
variability than A 1-40 in the monomeric conformation and
in ﬁbril morphology. The ﬁbril organization (and neurotox-
icity) of A 1-42 peptides also change when mixing WT M35L
and F19G mutants (Figure 1C).15 Zhang et al.36 suggested
an A 1-42 conformation with the C-terminus forming the
inside wall of a hollow core and the N-terminus playing a
role in the ﬁbrilization.
In addition to full-length A  peptides, a number of in vitro-
generated  -amyloid fragments were also observed to form
amyloid ﬁbrils. The sequences cover all A  peptide regions:
the N-terminus, middle, and the C-terminus regions. An early
study indicated that A 18-28,A  16-28,A  14-28,A  12-28, and
A 1-28 fragments were sufﬁcient to form amyloids; however,
A 20-28 did not yield a clear amyloid structure.74,75 Other
studies extended the fragment list to include A 11-25,76,77
A 16-22,78 A 10-23,79 and A 14-23.80,81 Figure 2A and B
provides EM images of the A 1-28 and A 10-23 amyloids,
respectively. For A 1-28, an assortment can be seen, including
linear, curvilinear, and rosette. The amyloid ﬁbril of A 10-23
has a diameter around 3 nm and a length of 500 nm, and for
the amyloid ﬁbril of A 1-28 the diameter is in the range of
6-8 nm and the length in the range of 120-160 nm. Among
these, the A 16-22 is one of the most studied fragments by
both experimental78,82 and computational approaches.83-90
The sequence of A 16-22 contains the KLVFF core. Starting
from the KLVFF, Tjernberg et al.91 systematically synthe-
sized 10 peptides with one more residue on each side
(A 6+x,30-x, where 0 e x e 9). Under their experimental
conditions, apart from three peptides (KLVFF, QKLVFFA,
and HQKLVFFE), all peptides formed amyloid ﬁbrils with
different morphologies.91
Extension from 1-28 to 1-30, 1-33, 1-36, and 1-39
presented ﬁbril morphologies similar to the full-length
A .92 These A  sequences are often used to represent full-
length A  in studies of amyloid formation and toxicity,
particularly those including A 25-35 and A 10-35, which are
believed to be the major responsible species.67,93-99 It appears
that A 25-35 could be more toxic than A 1-42, leading to a
rapid lysis of red blood cells97 and causing more extensive
oxidative damage.100 The short version of the A 25-35,
A 26-33, also forms thin long amyloids with a uniform
diameter of 5 nm101 (Figure 2C). A 10-35 has a supramo-
lecular structure similar to the full-length.67 Using compu-
tational approaches, Ma and Nussinov studied the A 10-35
fragment as a model to study the full-length A , and were
the ﬁrst to discover the U-turn conformation in A .46,83
The C-terminal region (residues 17-42) is mostly hydro-
phobic. One study observed that the transmembrane part of
A 29-42 forms amyloids faster than the full-length one, with
the order of A 29-42 > A 1-42 > A 1-32 > A 1-28;102 on the
other hand, another study found that this peptide scarcely
formed ﬁlaments. The few ﬁbril structures that could be
visualized had a diameter 2-3 nm and an average length of
50 nm.79 Hilbich et al.79 explored X-43 peptides (i.e., peptides
with an additional residue at the C-terminus). They found
that A 4-43,A  8-43,A  10-43, and A 12-43 form more stable,
tightly packed structures. They further observed that if the
Figure 1. Polymorphism of full-length A  peptides observed in experiments. (A) Transmission electron microscopy (TEM) images of
amyloid ﬁbrils formed by the A 1-40 peptide, prepared by incubation of A 1-40 solutions under quiescent dialysis conditions. Reprinted
with permission from ref 72. Copyright 2005 Science/AAAS. (B) Cryo electron microscopy (cryo-EM) of the structural persistence and
morphological diversity of A 1-40 ﬁbrils grown either in sodium borate (pH 7.8) at 22 °C or in phosphate-buffered saline (PBS) (pH 7.4)
at 37 °C. Both samples encompass evidently more than one ﬁbril morphology; Reprinted with permission from ref 73. Copyright 2009
Elsevier. (C) Electron microscopy (EM) images of morphologies of A 1-42 ﬁbrils. Reprinted with permission from ref 15. Copyright 2005
National Academic of Sciences, USA.
4822 Chemical Reviews, 2010, Vol. 110, No. 8 Miller et al.peptides are suspended in aqueous solvents, the N-terminal
can also promote amyloid formation: the ﬁbril formed by
the A 12-43 peptide is less stable than the one formed by the
A 1-43.79 A 34-42 formed rigid ﬁbrils of varying lengths
ranging from 10 to more than 300 nm; the single ﬁbrils were
slab-like with no apparent twist and had a width of 9 nm.
The assembly of several of these smaller ﬁbrils likely
constitutes twisted ﬁbers (Figure 2C).44,101 Generally, it seems
that amyloid ﬁbrils formed from C-terminal regions are less
smooth than those from the N-terminal region. Apart from
the A 34-42 fragment, the nonsmooth features of the p3
peptide ﬁbrils (A 17-40/A 17-42)103 (Figure 2D) further sup-
port the potential structural variability of the C-terminal,
which could relate to its hydrophobic nature promoting
polymorphism (see section 3.3).
Overall, in addition to ﬁber diffraction, which over the
years has provided a wealth of useful structural informa-
tion,104 computational studies of monomeric and oligomeric
structures of various fragments have clearly shown structural
ﬂexibility and oligomerization complexity, for example,
A 10-35,83,105 A 16-35,83,106 A 17-42,107,108 A 10-35 mono-
mers,109-114 A 21-30,115-118 A 13-23,91 A 1-28,119,120 and
A 14-23.91
3. Molecular Structures Underlying Amyloid
Polymorphism
The structural regularity of amyloids is not as good as
that of the highly ordered crystals; nonetheless, X-ray ﬁbril
diffraction has provided important structural features.
Examples of ﬁbril structure variability of A 11-25 and the
full-length A 1-40 obtained by X-ray diffraction are shown
in Figure 3A. Early diffractions revealed that all amyloids,
regardless of their sequences and secondary structures in
the native folded states, convert to  -sheets. The  -strand
backbone orientation is perpendicular to the ﬁbril axis,
which is termed cross-  structure (Figure 3C). The
distance between the  -strands is ∼0.5 nm, permitting
favorable backbone hydrogen bonds, and the layers are
usually separated by ∼1 nm allowing closely packed
 -sheet association (Figure 3B).77 With these basic features
unchanged, the amyloid polymorphism derives from the way
the  -strands associate into ﬁbrils. There are three major
structural features that may decide the overall amyloid ﬁbril
morphologies: (1) differences in backbone orientation; (2)
differences in backbone conformation; and (3) differences
in the way in which the oligomers, with almost identical
structure, associate. The combination of these three factors
can give rise to an enormous variation in conformational
Figure 2. Polymorphism of A  peptide fragments as observed in EM images. (A) A 1-28 ﬁbrils, negatively stained, are periodically
stained along some of their edges (indicated by arrows). Fibril ends appear to splay or unfurl. Reprinted with permission from ref 75.
Copyright 1987, directly permission from Dennis J. Selkoe. (B) A 10-23 ﬁlaments prepared in vitro. The ﬁlaments are irregularly twisted
around each other. Reprinted with permission from ref 79. Copyright 1991 Elsevier. (C) A 26-33 and A 34-42 ﬁbrils. A 26-33 ﬁbrils are thin
and uniform as compared to those of A 34-42 ﬁbrils and appears to be comprised of ﬁbril pairs. At low magniﬁcation, A 34-42 shows two
types of assemblies: twisted ﬁbrils and untwisted narrow ﬁbrils. At higher magniﬁcation, twisted ﬁbrils and periodic deposition of enhanced
staining (indicated by arrows) are observed. Reprinted with permission from ref 101. Copyright 1990 American Chemical Society. (D)
A 17-40 form protoﬁbrils (top) and a mature ﬁbril of A 17-42 (bottom). Reprinted with permission from ref 103. Copyright 2003 American
Society for Biochemistry and Molecular Biology.
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phology. This section demonstrates and discusses these
structural features in detail.
3.1. Polymorphic Backbone Organizations within
and between Sheets in Amyloid Fibrils: Potential
Combinations
The detailed structural variations of tightly packed (“steric-
zipper”) segments of amyloid-forming peptides43 and the
amyloid backbone associations can be applied to other short
peptides like A  fragments. In principle, there are thousands
of possible patterns of intra- and inter-residue amyloid ﬁbril
backbone strand organizations for in-register and out-of-
register interactions. Figure 4 highlights several representative
in-register alignments with double-layered  -strand segment
arrangements within and between sheets. Figure 4A-D
presents organizations where each layer has parallel strands;
within these, parallel orientations between the two layers are
illustrated in Figure 4A and B and antiparallel orientations
between the two layers of the segment in Figure 4C and D.
Figure 4E-H presents antiparallel arrangements in each
layer, with Figure 4E-G illustrating parallel orientation
between the two layers and Figure 5H an antiparallel
orientation. Other possible models of backbone organization
can consist of parallel dimers (or trimers, or variable oligomer
sizes, etc.) associated in an antiparallel orientation.
Short segments are more convenient systems, because
their smaller sizes make them easier to study experimen-
tally and computationally; at the same time, the basic
principles are likely to be unchanged. Most studied A 
segments25,44,64-68,74-76,78-80,91-96,101 are organized in an in-
register, parallel arrangement; however, some present a
preferred antiparallel organization (enumerated in Table
1). While only some of the potential organizations have
been observed, others may also exist, except that their
populations may be too low to be observed by experiment.
Short fragments (less than 15 residues length) tend to have
antiparallel  -strands. On the basis of X-ray diffraction and
Ala16A 1-28 mutant substitution comparison, the  -strands’
orientation of A 1-28 ﬁbrils was proposed to be all-antipar-
allel (as in Figure 4H).75 As shown in Figure 3B, the A 11-25
has antiparallel  -strands within the sheet; however, the
sheet-sheet orientation is parallel (as shown in Figure 4G).77
For the A 14-23, the antiparallel conformation has also been
proposed from NMR information.80 For A 16-22, which is
one of the most studied fragments, both experimental and
computational studies suggest antiparallel organization.83-90
In the C-terminal region, A 34-42 was also shown by ssNMR
to be antiparallel.44 IR spectroscopy indicates that amyloid
Figure 3. (A) EM images and X-ray diffraction patterns of cross-  ribbons for A 11-25 (I) and (III) and A 1-40 (II) and (IV). The measured
widths of the ﬁbrils are ∼5 nm for A 11-25 and ∼7 nm for A 1-40 (see arrows in I and II). These are wide-angle X-ray patterns; a*i st h e
vertical ﬁbril axis;. Reprinted with permission from ref 77. Copyright 2003 Elsevier. (B) Model of A 11-25: (I) Antiparallel organization.
The 0.47 nm spacing (a-direction) is controlled by hydrogen bonding, and the molecules are ∼5 nm in length. (II) Direct stacking that
would generate an orthorhombic unit cell. (III) Stacking with a slip of 0.697 nm (one  -sheet crimp; one structural repeat in the c-direction)
parallel to the c axis. This stacking arrangement gives rise to monoclinic unit cell. Reprinted with permission from ref 77. Copyright 2003
Elsevier. (C) Illustration of cross-  arrangement in amyloids; the peptide backbone  -strands are perpendicular to the ﬁbril axis
(arrow).
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less ordered structure (loops or  -turns).79
Polymorphism can thus arise from different  -strand
orientation and side-chain registration. For example, A 16-22
can have two stable antiparallel orientations (Figure 4G and
H)83 as both have in register side-chain interactions. Recent
experiments also revealed an out-of-register, one residue shift
in the antiparallel orientation.82 A 25-35, a central A  region
fragment, may have both parallel (Figure 5A) and antiparallel
(Figure 5B) orientations; both arrangements are probably
stabilized by hydrophobic interactions.121 However, the
parallel orientation could be more ordered due to a strong
steric zipper match of central Ile residues (Figure 5A and
B); Ile was proposed to promote amyloid formation in
general.122 As indicated in Figure 5, A 25-35 gives rise to
different morphologies depending on whether it is oriented
in parallel or antiparallel. A similar scenario arises from
parallel or antiparallel arrangements of the peptide hI-
APP20-29, corresponding to the amyloid of the SNNFGAILSS
region of the human islet amylin polypeptide.123 There,
Figure 4. Potential architectures of strand organizations in amyloid ﬁbrils. Interactions (in dotted lines) are shown between the ﬁrst layer
(blue) and the second layer (red) for (A) parallel to parallel, face-to-face orientation; (B) parallel to parallel, face-to-back orientation; (C)
parallel to antiparallel, face-to-face orientation; (D) parallel to antiparallel, face-to-back orientation; (E) antiparallel to antiparallel, face-
to-face orientation, parallel to parallel between layers; (F) antiparallel to antiparallel, face-to-back orientation, parallel to parallel between
layers; (G) antiparallel to antiparallel, face-to-back orientation, parallel to parallel between layers; and (H) antiparallel to antiparallel, face-
to-back orientation, antiparallel to antiparallel between layers.
Figure 5. Illustration of A 25-35 in parallel (A) and antiparallel (B) arrangements. The sticks are peptide backbone, and the balls are Ile
residues. Parts (C) and (D) illustrate the U-turn structures of Ma-Nussinov-Tycko (ref 46) and Lu ¨hrs et al. (ref 15), respectively.
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forms of amylin ﬁbrils, responsible for type II diabetes.123
3.2. Polymorphism in the U-Turns in Amyloid
Fibrils
Full-length and other long A  fragments, especially those
containing central and C-terminal regions (for example,
A 10-35), mostly have parallel  -strands orientation. How-
ever, the tendencies for a U-turn backbone conformation in
the central region provide yet another variable feature for
A  peptides. The ﬂexibility of the turn region allows the
A  peptide to adopt slightly different turn types leading to
different amyloid morphologies.
Two models of the three-dimensional structures of A 1-42/
A 1-40 ﬁbrils were proposed and veriﬁed experimentally.46
The ﬁrst, Ma-Nussinov-Tycko model,46,68 presents a double
layer structure with residues 10-22 and 30-40 forming
 -strands and residues 23-29 a bend or loop. The two
 -strands form two separate, in-register, parallel  -sheets,
which can interact with one another due to the intervening
bend segment (Figure 5C). The second model by Lu ¨hrs et
al.15 presents a parallel single layer structure of A 1-42 ﬁbrils
based on hydrogen/deuterium exchange NMR data, combined
with side-chain packing constraints from pairwise mutagen-
esis, ssNMR, and high-resolution cryo-EM (Protein Data
Bank code, 2BEG). Observations based on these experiments
indicated that residues 1-16 are structurally disordered and
residues 17-26 and 31-42 form two  -strands,  1 and  2,
respectively, connected by a U-turn spanning four residues,
27-30 (Figure 5D). This model also suggested that parallel
oligomers associate in parallel. The difference between the
two U-turns is that in the Ma-Nussinov-Tycko model it is
tighter, thus allowing the C-terminal residues to interact with
up to N-terminal residue Tyr10;46,68 on the other hand, the
Lu ¨hrs’ turn is looser, with Lys28 shifted, and consequently
the C-terminal region can only reach residue Leu17.15
Conformational differences in the U-turn can be expected
to lead to polymorphic sheet registration and  -strand
organization at the termini. For the A  case, although both
models suggest parallel sheets, the two models differ in the
U-turn conformation, leading to different extents of disorder
in the N-terminal. In Tycko’s model, the U-turn segment
extends over 7 residues and in Lu ¨hrs’ only over 4. As to the
N-terminal, the disordered segment in Tycko’s model
includes 8 residues, whereas in Lu ¨hrs’ it is 16, because the
N-terminal projects into the solvent much beyond the
C-terminal, thus without tight vdW interactions. This also
affects the sheet-sheet registration. Thus, polymorphism in
parallel A 1-42/A 1-40 (or fragments that include the U-turn
segment and the two  -strands, such as A 10-35) appears to
be largely governed by the U-turn conformational variability,
and an interplay between various factors can also expected
to play a role in polymorphism. Consistently, a combined
experimental and simulations study revealed varied U-
turn shapes forming by different segment sizes: A x-42
(x ) 29-31).124 Recent simulations presented variations for
A 10-40/10-42
125 and A 1-42
126-128 due to the U-turn conforma-
tion.
It is frequently noted in the literature that the amyloid ﬁbril
is a supramolecular structure composed of several protoﬁbrils
wound around each other mostly in a left-handed twist along
their main axis.35,129-137 Different U-turn conformations can
affect the twist angles leading to different oligomer and ﬁbril
morphologies. Presumably, a difference in the U-turn
conformation exhibits a difference in the interstrand angle;
a change of even a fraction of a degree can signiﬁcantly
change the twist. The change will not present a right-handed
twist, but will present different EM morphologies.
3.3. Polymorphism in Association of -Sheet
Oligomers
Apart from the large structural variations described above,
small changes in side-chain orientation or in the environment
(e.g., pH, temperature, concentration, salt, agitation, synthetic
versus brain-seeded) may lead  -sheet oligomers to associate
in different ways, leading to amyloid polymorphism with
similar molecular organizations. This has been illustrated in
A 1-40 ﬁbril morphologies. Recently, polymorphism of
A 1-40 at the protoﬁbril level had been obtained by Mein-
hardt et al.73 They classiﬁed 12 single A 1-40 amyloid ﬁbrils
differing in the ﬁbril width and twist angles, all forming
under the same solution conditions. As shown in Figure 6A,
the differences derive from the protoﬁbril associations with
altered contact areas. One of the distinct features of the
polymorphism observed by Meinhardt et al.73 is that 2-fold
symmetry is mostly conserved for all 11 amyloid ﬁbril
models (except ﬁbril model 12) constructed from cryo-EM
(not shown here). Fibril model 12 has a different symmetry
and organization: even though it still consists of two
protoﬁbrils, they are offset with respect to the central ﬁbril
axis, alternating from the left-handed to the right-handed and
with different mechanical properties.73 A larger deviation
from the 2-fold symmetry of A 1-40 ﬁbril morphologies has
been observed by Paravastu et al.138 They found two A 1-40
ﬁbril morphologies differing in several features: the overall
symmetry (2-fold versus 3-fold); the conformation of the
Table 1. Features of the Full-Length A Amyloid, A Segments, and 2M (K3)
segment
length of segment
(number residues)
percentage of
hydrophobic
residues
percentage of
hydrophilic
residues
percentage of
charged residues
net charge of
monomer’s
segment
conﬁguration of
amyloid ﬁbril ref
A 1-42/A 1-40 40/42 48 40 21 -3 parallel 15, 25, 68
A 10-35 26 46 42 19 -1 parallel 24, 67, 93-96
A 17-42 26 62 19 12 -1 parallel 107, 108
A 14-23 10 50 50 30 -1 antiparallel 80
A 34-42 9 78 0 0 0 antiparallel 101
A 1-28 28 32 61 32 -3 antiparallel 75
A 16-22 7 71 29 29 0 antiparallel 78
A 11-25 15 47 47 27 -2 antiparallel 76
A 1-9 92 2 6 7 4 4-2 disorder
(random coil)
25
A 24-30 72 9 4 3 1 4+1 loop 25, 64, 65
K3 22 41 32 18 -2 parallel 150
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contacts (Figure 6B).138 Recently, Paravastu et al.139 have
shown that the predominant molecular structure in brain-
seeded with A 1-40 ﬁbrils differs from the structure of purely
synthetic ﬁbrils that were previously characterized.68,138
Fandrich et al.140 deﬁned polymorphism based on variations
in (1) the protoﬁlament number, (2) the protoﬁlament
arrangement, and (3) protoﬁlament substructures.
Nonetheless, overall, A 1-40 ﬁbrils present regular smooth
amyloid morphologies. Many smaller fragments, particularly
those containing C-terminal residues (like the A 17-42 and
A 34-42 ﬁbrils, Figure 2), are much more irregular as
compared to the full-length A 1-40/A 1-42. The potential
variability of the ﬁbril morphologies for these amyloids is
expected to be much more diverse.
4. Other Protein/Peptide Sequences Also Have
Polymorphic Fibrils Structures
Polymorphism in amyloid ﬁbrils has also been observed
for other proteins, for both designed model systems and
disease-related proteins. For example, Verel et al.141 dem-
onstrated polymorphism in a de novo designed peptide model
system (Ac-SIRELEARIRELELRIG-NH2), which is ex-
pressed by different arrangements of the  -sheets in the
oligomer. Depending on the pH, the model peptide can shift
the registration of residues and still keep an antiparallel
 -sheet organization. Disease-related amyloid polymorphism
can be illustrated by the cross-seeding ﬁbrilization of the
Q/N-rich protein, which leads to pathological diversity in
Huntington disease with the morphologies differing with the
segment size.142
Among the other species that form amyloid ﬁbrils is  2-
microglobulin ( 2M), which is a component of type I major
histocompatibility antigen. In patients on long-term hemo-
dialysis,  2M can aggregate into amyloid ﬁbers and cause
dialysis-related amyloidosis.143-149 The ssNMR structure150
of a 22 amino acid (Ser20-Lys41) region (the so-called K3)
that may have a role in amyloid formation of  2M was
investigated using a series of peptides obtained by cleaving
with Achromobacter protease I.151 Interestingly, K3 also
shares similar U-turn shape in the  -sheet organization with
a parallel orientation.150 K3 was also shown to form ion-
conducting channels in membranes.51 Other key regions in
 2M shown to be important in ﬁbril formation have also been
investigated by Radford,152,153 Eisenberg,154-156 and Mirank-
er157 and their co-workers.  2M segments also exhibit poly-
morphism. The K3 peptide may form two types (f218 and
f210, which has more  -sheet and is thinner and longer) of
amyloid ﬁbrils differing in their amino acid contacts between
the  -sheets, and both ﬁbrils were reproduced by seeding,
showing the template-dependent propagation of a ﬁbril’s
conformation.158 Upon repeated self-seeding, f218 ﬁbrils
were gradually transformed into f210 ﬁbrils, revealing the
conformational maturation to higher  -sheet content. Full-
length  2M has been shown to form at least three different
subunit interfaces in the ﬁbril structures assembled from
globular tetrameric units.159 The elegant cryo-EM maps
(Figure 7) illustrate three-dimensional reconstructions of type
A (Figure 7A and C) and B (Figure 7B and D) forms of the
homopolymeric assembly of  2M. The two ﬁbril types have
the same underlying organization that differs only in the
orientation of the two stacks, either parallel or antiparallel.159
Figure 6. Polymorphism of the A 1-40 peptide based on different associations of the protoﬁbrils. (A) A structural model of protoﬁlament
core topology of ﬁbrils 1, 5, and 11, observed from Meinhardt et al.73 Side view of the ﬁbrils with two protoﬁlament cores modeled into
the density (top) and contoured density cross sections of the ﬁbrils superimposed with two protoﬁlament cores (bottom). Each protoﬁlament
core comprises a pair of two  -sheet regions: interface (yellow) and outside (blue). Reprinted with permission from ref 73. Copyright 2009
Elsevier. (B) Experiment-based structural models of A 9-40. (I) A ribbon presentation of the lowest-energy model for ﬁbrils with twisted
morphology. (II) Atomic representation, viewed down the ﬁbril axis. Hydrophobic, polar, negatively charged, and positively charged amino
acid side-chains are green, magenta, red, and blue, respectively. Backbone nitrogen and carbonyl oxygen atoms are cyan and pink. (III)
Comparison of twisted (upper) and striated ribbon (lower) ﬁbril morphologies in negatively TEM images. (IV) Atomic representation of a
model for striated ribbon ﬁbrils developed previously by Petkova et al.68,72 Reprinted with permission from ref 138. Copyright 2008 National
Academic of Sciences, USA.
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Yeast prion variants have been identiﬁed on the basis of
stabilities and phenotypic intensity160-163 relating to prion
strains.164-166 Fibril structural polymorphism has been pro-
posed as the culprit in the species barriers167,168 with the
amyloid-forming domain in prion ﬁlaments exhibiting poly-
morphic variation.169 Prion amyloid structural variations have
been observed with differences in long-range axial repeats,
diameter, and/or the number of protoﬁlaments.169 Polymor-
phic prion structures may form due to conformational self-
seeding characteristics, kinetics, and stability.170 Fibrils that
are conformationally less stable produce shorter pieces upon
fragmentation.171 The more stable ﬁbril core regions were
also identiﬁed.172
Amyloid polymorphism has also been observed for the
isletamyloidpolypeptide(IAPP)amylin,byexperiment123,173,174
and simulations.175 Amyloid formation by amylin leads to
cell death and is related to type II diabetes. It was
demonstrated that conformational polymorphism of IAPP
peptides in different microenvironments correlates with
cellular toxicity and proteasomal inhibitory activity.123,173,174
The peptide hIAPP20-29, 20NNFGAILSS29, may have two
amyloid-like forms, which have distinct structures at the
molecular level. One form has parallel  -strands and the other
antiparallel, with both stabilized by hydrophobic contacts
with similar energy.123,173,174 Hydrophobic interactions can
weaken under high hydrostatic pressure. However, fragments
1-19 and 1-29 of IAPP are resistant to pressure, suggesting
more densely packed aggregate structures.123,173,174
5. Sequences and Physicochemical Properties
That Can Affect Amyloid Fibril Architectures
Amyloid ﬁber growth involves folding and association via
conformational selection of peptide monomers.57,70,176,177
Prediction of the aggregation rate of different A  segments
may be performed by a model based on the physicochemical
properties of the segment.178 The  -sheet in A  segments,
while deﬁned by interstrand hydrogen bonding, owes its
stability mainly to intra- and intersheet side-chain packing.179
The presence of intermolecular hydrogen-bonding interac-
tions along the entire length of the peptides further stabilizes
the oligomers and is critical in determining the ﬁbril
structure.180 As can be seen from Table 1, some of the A 
peptide segments adopting  -strand conformations form
amyloid ﬁbrils in a parallel orientation and others in an
antiparallel orientation. This section examines the properties
of these fragments that can affect their preferred architecture
such as segment length, hydrophobicity, hydrophilicity, and
charge. Table 1 also summarizes the characteristics of full-
length A  and its segments and the K3 segment of  2M for
which there are ssNMR data.
Different lengths of A  segments have different morphol-
ogies. As can be seen from Table 1, there is a general trend:
longer segments prefer a parallel orientation. Segments with
more than 15 residues are organized in parallel; under 15
residues they prefer an antiparallel arrangement probably due
to repulsion by the charged termini in the parallel organiza-
tion, which would need to be overcome. For short peptides,
the antiparallel arrangements can be favored by better
backbone hydrogen bonding, backbone dipole-dipole in-
teraction, and charge-charge interaction among the terminus
residues. However, longer fragment such as A 1-28 favors
antiparallel arrangement, while the parallel arrangement is
favored by the short non-A  GNNQQNY sequence.170,181-184
Obviously, not only the length determines the stability of
the ﬁbril, but also the nature of the residues along the
segment that interacts. For example, the available 15 mi-
crocrystal structures of cross-  spines exhibit parallel ar-
rangements for peptides free of any charged residues.43
5.1. Hydrophobicity Can Increase Amyloid
Polymorphism
As can be seen from Table 1, the percentage of the
hydrophobic residues is above 40% for all  -strand segments
presented here, and some of these segments are also enriched
in hydrophilic residues. There are two hydrophobic rich regions
in A 1-40/A 1-42 peptides, segments 17-22 (KLFFA) and
30-42 (AIIGLMVGGVVIA). ssNMR indicates that A 10-35,
A 1-40, and A 1-42 ﬁbrils are organized in parallel, whereas
A 16-22,A  34-42, and A 14-23 are antiparallel. Most of these
consist of hydrophobic segments believed to be crucial for
aggregation.70,185
Hydrophobic interactions are the driving force for
protein-protein association, including protein aggregation;122
they largely control the stability and therefore determine the
organization. In  -sheets, stabilization by hydrophobic
interactions could maximize when the interactions are
between stacked identical residues, which is the case in a
parallel organization.186 For example, 15 interactions between
in-register hydrophobic residues of two  -strands stabilize
Figure 7. Variability in  2-microglobulin ﬁbril structure. Reprinted
with permission from ref 159. Copyright 2009 Elsevier. Three-
dimensional reconstructions of the type A and type B forms of  2-
microglobulin ﬁbrils. Side views of an A-type ﬁbril (A) and a B-type
ﬁbril (B). One dimeric density unit is indicated by a red box in
(B). The directions of the half-ﬁbrils are indicated by arrows below
the maps. Cross sections of the A type (C) and B-type ﬁbrils (D)
show that the structures are formed of crescent-shaped units stacked
back-to-back. (E) Superposed contour plots of the A (lilac) and B
(green) repeat units, showing that the two ﬁbril types have the same
underlying organization that differs only in the orientation of the
two stacks, either parallel or antiparallel.
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six interactions between hydrophobic residues in the anti-
parallel organization (Figure 8A). Parallel  -sheet organiza-
tion juxtaposes the hydrophobic segments of neighboring
peptide chains, while an antiparallel organization does not.
Therefore, the preferred orientation of the  -strands for
A 10-35 is parallel.
A 16-22 is stabilized by hydrophobic interactions between
consecutive  -strands along the ﬁbril axis. It seems that both
parallel and antiparallel orientations are favored for A 16-22,
with both arrangements presenting central hydrophobic
sequence, including the strongest Phe-Phe hydrophobic
interaction. However, A 16-22 has positively charged Lys at
the N-terminus and negatively charged Glu at the C-terminus.
Parallel  -sheet organization will create electrostatic repul-
sion destabilizing the ﬁbril, whereas an antiparallel  -sheet
organization simultaneously juxtaposes the central hydro-
phobic segment and minimizes the electrostatic energy
(Figure 8B). Ma and Nussinov83 studied the stability of
A 16-22 and concluded that for the antiparallel model the
hydrophobic interactions appear to dominate in this short
segment. Nonetheless, as discussed in the next section,
because hydrophobic interactions in the parallel A 16-22
organization are strong, they can overcome the electrostatic
destabilization induced by ﬂexible side-chains at the termini,
leading to a parallel A 16-22 arrangement, as seen from
Figure 8B. Thus, while both organizations are likely to exist,
the antiparallel one presents higher population. A similar
picture is presented by A 34-42. Because it consists of a single
hydrophobic segment with a positively charged N-terminus
and negatively charged C-terminus, hydrophobic contacts
maximize in either parallel or antiparallel structures, while
electrostatic interactions would be expected to favor the
antiparallel structure (Figure 8C).
Hydrophobic interactions are nonspeciﬁc, which could
underlie the diversity of possible interaction patterns. There-
fore, amyloids dominated by hydrophobic interactions could
easily present polymorphic behavior. In the case of A 16-22,
an in-register antiparallel organization (Figure 8BII) has been
shown to be preferred. However, a new arrangement with
one residue shifted and the backbone ﬂipped (Figure 8BIII)
is possible under acidic conditions.82 It can be seen that both
arrangements in Figure 8BII and BIII present favorable
hydrophobic interactions; however, the antiparallel one
residue-shifted arrangement (Figure 8BIII) may have better
aromatic interactions derived from two nearby Phe residues.
The importance of aromatic interactions between two
 -sheets in protein aggregation has been emphasized by Gazit
and co-workers187 who suggested that aromatic interactions
play a key role in molecular recognition, self-assembly, and
amyloid formation.187 Makin and co-workers188 further
conﬁrmed that aromatic residues that are capable of π-π
stacking are important for amyloid ﬁbril formation.
Apart from the role of the hydrophobic effect in the
polymorphic character of the  -strands arrangement within
 -sheets, the diversity of hydrophobic interactions between
protoﬁbrils can also contribute to amyloid polymorphism.
In the case of A 1-40, the highly hydrophobic C-terminal
region provides many possible interaction interfaces for
2-fold or 3-fold arrangement patterns (Figure 6).73,138
5.2. Charged Residues Require a Speciﬁc Match,
thus Decreasing Amyloid Diversity
Electrostatics can play a crucial role in A  ﬁbrils.75,76,189,190
At ﬁrst glance, the charged nature of many amyloid-forming
peptides can increase the solubility and thus decrease their
intrinsic ability to form  -sheet based aggregates. However,
in certain cases, charged residues may help the peptides to
form amyloids, as indicated by the full-length A  peptide,
which forms ordered ﬁbrils much more easily than the shorter
and more hydrophobic aggregative A 17-42.
Figure 8. Illustration of the organization of the hydrophobic residues (black) and the charged residues (red), and their charge interactions
(brown) in parallel and antiparallel alignment for (A) A 10-35, (B) A 16-22, and (C) A 34-42 fragments.
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A  segments have  -strands that are negatively charged,
some are positively charged, and others have a net charge
of zero. It appears that  -strand organization in parallel or
antiparallel does not depend on the segment net charge. The
percentage of the charged residues in the segment does not
determine the arrangement of the  -strands either. However,
charge-charge interactions between sheets are important for
ﬁbril formation and residues with complementary charges
promote ﬁbril formation. Therefore, the positions of the
charged residues along the sequence of the segment are
important for the stabilization of the amyloid ﬁbril and affect
the arrangement of the  -strands.
A parallel organization of A  forms homostacking (identi-
cal amino acids stacked on top of each other). Stacking of
chemically similar charged residues in a parallel orientation
creates electrostatic repulsion. In contrast, the antiparallel
orientation is favored by electrostatic interactions between
the C- and N- termini of neighboring molecules in a  -sheet
(e.g., the positive amino and negative carboxylate groups at
the ends of uncapped A 34-42 as illustrated in Figure 8) or
by oppositely charge residues (e.g., positively charged Lys
and negatively charged Glu side chains in capped A 16-22
as described in Figure 8). Thus, preferred ﬁbril architecture
maximizes the number of hydrophobic and attractive elec-
trostatic interactions.
Because hydrophobic interactions are nonspeciﬁc, the
attractive electrostatic interactions limit the variation of the
amyloid arrangement. The A 11-25 fragment is a good
example in this case. As compared to A 1-40, the A 11-25
fragment can form a ﬁbril, which yields a better quality and
higher resolution X-ray diffraction data (Figure 3A),77
indicating lower structural ﬁbril diversity. Expanded from
A 16-22, the charged pattern in A 11-25 increases the weight
of electrostatic interactions as compared to the (unchanged)
hydrophobic interactions (Figure 3B). In the N-terminus, two
His residues (His13, His14) increase the positive charge in
the Lys16 region, while Asp23 added to Glu22 leads to a
more negative C-terminus. As a result, the strong electrostatic
interactions make the in-register antiparallel alignment of
A 11-25 highly favorable, with other alternatives hard to
compete. Clearly, the strong electrostatic interaction con-
tributed to the structural uniformity of the A 11-25 amyloid.
5.3. Steric Zipper Could Increase or Decrease
Amyloid Diversity
Preferred ﬁbril architecture is also stabilized by tight van der
Waals (vdW) packing between  -sheets. Steric zippers (that is,
tight packing) appear a generic structural motif of the amyloid
protoﬁlament,170,191-193 because good geometrical ﬁt provides
favorable vdW interactions and constrains side-chain move-
ment. For example, in the amyloid-like GNNQQNY ﬁbril,
the interactions are maximized by very tight side-chain
packing.170,192 In the case of this all-polar sequence, the strong
steric zipper match provides a dominant amyloid-like crystal,
making an atomic resolution structure possible.
Studies of the stability of the islet amyloid polypeptide
segments NFGAIL and NFGAILSS194 have shown that
interactions between hydrophobic residues and between
aromatic residues dominate. However, recently other ar-
rangements with good geometric ﬁt between  -sheet layers
have also been shown to be possible,123 suggesting that for
the islet amyloid polypeptide segment NFGAILSS, a tight
steric zipper packing can occur in more than one way,
increasing polymorphism. Recently, Park et al.195 studied the
polymorphism for the steric zipper patterns of various short
peptides while considering the kinetics and the thermody-
namics as driving forces for the structural selection.
For the A 11-25, a steric zipper can contribute to decreased
polymorphism. The strong electrostatic interactions prefer
the in-register antiparallel  -sheet. Considering only elec-
trostatic interactions, the amyloid structure of A 11-25 can
have an arrangement as in Figure 4H, where electrostatic
interactions are also maximized between sheets. Early work
indeed suggested this architecture for the 11-24 region in
A 1-28.75 However, due to a better steric match between
parallel  -sheets, the A 11-25 adopts the Figure 4G arrange-
ment (also see Figure 3B) to allow optimized hydrophobic,
electrostatic, and steric zipper (vdW) ﬁt.
6. Polymorphism in Metal-Binding Sites in
Alzheimer A Amyloid: Zn2+,C u 2+,F e 3+, and Al3+
The most prevalent metal ions in biological systems, such
as Zn2+,C u 2+, and Fe3+, are known to be essential for normal
brain function and development.196,197 Disrupted cellular
homeostasis of these ions is thought to play a central role in
the aggregation and neurotoxicity of A .198,199 These metal
ions are markedly enriched in A  plaques200-210 and may
act as seeding factors. In contrast, while a higher concentra-
tion of Al3+ has been established in AD patients’ brain,211-214
the mechanism of its pathogenesis in AD is still debated.215-218
Nonetheless, experiments clearly demonstrated that Al3+ ions
do play a role in A  aggregation and in neurotoxicity.219-224
Interactions with these metal ions may explain the increased
involvement of soluble toxic oligomeric species.225 To date,
the conformation of A  complexes with metal ions is still a
major challenge. Open questions include (1) which residues
in the A  peptide interact with the metal ion; (2) are there
different conformations with different residues coordinating
the metal ions; and (3) among these, which are preferred.
Characterization of the intrinsic conformational properties
of A 1-40/A 1-42 oligomers complexed with metal ions is
important to understand the effect of metal ions on A 
aggregation. So far, A  binding sites for Zn2+ and Cu2+ were
studied extensively, but there is lack of data for Fe3+.
Polymorphism can be observed in Cu2+ complexes with
A  amyloid. Possible Cu2+ coordinating residues include
histidines (His6, His13, His14), tyrosine (Try10), aspartate
or glutamate (Asp1, Glu3, Asp7, Glu11, Glu22, Asp23),
methionine (Met35), deprotonated amides of peptide back-
bone, or carbonyl groups.206,226-231 The most common
residues are located at the N-terminus of A : the binding
site for Cu2+ was proposed to consist of the three histidines
(His6, His13, and His14) and Tyr10.205,226,232-238 Further,
studies demonstrated that the Cu2+ binding site can involve
Asp1239,240 or Glu11.240 A recent study of the Cu2+ binding
site in the rat A 1-28 fragment revealed that Cu2+ binds to
Asp1, His6, and His14.241 His13 is absent in rat A 1-28.
Recent simulations suggested that Cu2+ coordinates with
His13 and His14 of each two A  peptides.242 These studies
suggest various possible conformers. We therefore conclude
that A  amyloid with different experimentally detected Cu2+
binding sites depends on the populations of the various
morphologies under different conditions.
The zinc binding site in A  is also located at the disordered
N-terminal (Asp1-Lys16). Seven potential N-terminal resi-
dues can bind Zn2+: Asp1, Glu3, His6, Asp7, Glu11, His13,
and His14. As for the Cu2+ binding site, in the case of Zn2+,
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terminal segment coordinate with Zn2+.226,227,237,243-260 Re-
cently, three different models of Zn2+ binding to A  were
observed by experiments: First, the NMR structures of
Zn2+-A 1-16 in aqueous solution at pH 6.5 and 7.4 showed
that Zn2+ is bound to these three histidines and to the two
carboxylic groups of Glu11.252 Second, an NMR study on
Zn2+-A 1-28 in sodium dodecyl sulfate (SDS) micelles at
pH 7.5 and a temperature of 298 K proposed a tetra-
coordination of Zn2+ by His6, Glu11, His14, and Asp1 at
the N-terminus for rat A 1-28, and penta-coordination of Zn2+
by His6, Glu11, His13, His14, and Asp1 at the N-terminus
for human A 1-28.257 The third model is based on X-ray
absorption spectroscopy (XAS) in which Zn2+-A  com-
plexes are coordinated with four histidines (His13 and His14
of two monomers), indicating that each metal ion is shared
by two A  peptides.258 A  oligomers coordinated with Zn2+
can be modeled using experimental data as shown in Figure
9. See an additional recent reference in the note added in
proof. We therefore propose that Zn2+ can coordinate the
N-terminal domain in different A 1-42 oligomer morpholo-
gies. The prevailing organization and the probability to detect
certain morphologies depend on experimental conditions such
as temperature, Zn2+ concentration, and pH. Oligomer
stability depends also on its size, in particular when dealing
with Zn2+ in the N-terminal.
Much less is known about the preferential regions of Al3+
b i n d i n gt oA  . Fasman261 proposed that Al3+ coordinates with
Asp, Ser, Tyr, and Glu in A . Recently, Ricchelli et al.262
suggested that Al3+ may coordinate with residues in both
the hydrophilic segment (1-16) and the hydrophobic se-
quence 20-35 in the A  peptide, and thus Al3+ binding site
is less restricted than that of Zn2+ or Cu2+, which are conﬁned
to the N-terminal. Thus, polymorphic Al3+ A  complexes
are also expected.
7. Polymorphism in Soluble A Oligomers Leads
to Different Mechanisms of Toxicity
Amyloid toxicity is the outcome of Ca2+ conductance
through the membrane, and, as described below, polymorphic
A  oligomers can differ in their mechanisms of toxicity. A 
toxicity was ﬁrst identiﬁed by formation of A 1-40 cation
selective channels in planar lipid bilayers fused with lipo-
somes and in acidic bilayers.263 The A 1-40 channel in the
solvent-free membrane patch presented multiple cation
selectivity and sensitivity to tromethamine, which suggested
that in cells the ion ﬂuxes would disrupt cellular homeosta-
sis.263 Toxic Ca2+ conductance through unregulated pores
or ion channels formed by A  or its fragments was also
supported by other studies264-267 and appears universal for
amyloidogenic peptides. The channels are polymorphic48,50
and differ from conventional ion channels.268 Even though
it is currently believed that small oligomers play critical roles
in ion-channel formation, the relationship between amyloid
deposition and cellular toxicity is still controversial, and the
similarity to bacterial pore-forming toxins is challenging to
study.269
Other soluble A  forms, which are broadly named as
amyloid  -derived diffusible ligand (ADDLs), have different
morphologies and were proposed to have different mecha-
nisms. Unlike ion channels observed in bilayers, ADDLs
were shown to be linked to neuron toxicity, mostly via
binding to protein receptors.270 ADDLs are highly ordered,
binding to a speciﬁc subset of postsynaptic proteins. In
particular neural signal transduction pathways, ADDLs can
impair synaptic plasticity and associated memory dysfunction
during the early stage of AD.
In 2005,271 it was observed that a homogeneous and stable
globular amyloid  -peptide oligomer can be easily prepared
in vitro. This globular amyloid  -peptide was present in the
Figure 9. Various conformations of Zn2+-A  monomer complexes: (A) NMR structural model for Zn2+-A 1-16 (ref 252), (B) NMR
structural model for human Zn2+-A 1-28 (ref 257), (C) NMR structural model for rat Zn2+-A 1-28 (ref 257), and (D) X-ray spectroscopy
model of Zn2+ binding to His13 and His14 of 2 adjacent A  peptides (ref 258).
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transgenic mice. The pure, water-soluble globular 60 kDa
oligomer was reported to have 12 A  monomers. This
“globulomer” is a persistent structural entity apparently
formed independently of the ﬁbril aggregation pathway.
Unlike ADDLs, the A 1-42 globulomer binds speciﬁcally to
dendritic processes of neurons but not glia in hippocampal
cell cultures and completely blocks long-term potentiation
in rat hippocampal slices. Similar to ADDLs, the globulomer
also relates to early AD. In 2006, another species smaller
than the globular 60 kDa oligomer, A *56, was reported as
a soluble oligomer causing memory deﬁciency in middle-
aged mice.225 However, on the basis of biochemical proper-
ties and immunospeciﬁcity, it was argued to be unlikely to
bind to receptor proteins, and instead to impair memory
independently of plaques or neuronal loss.225 A larger soluble
oligomer, “amylospheroids” (ASPDs),272,273 was also ob-
served, with sizes around 10-15 nm. These spherical A 
assemblies have high-mass (more than 100 kDa) and can be
detected in AD and Lewy body (DLB) brains, using ASPD
tertiary structure-dependent antibodies. ASPDs bind presyn-
aptic targets on mature neurons with different toxicity from
other ADDLs. Finally, cellular prion proteins (PrPCs) were
recently identiﬁed as high-afﬁnity cell-surface receptor for
soluble A  oligomers on neurons,274 but the interaction does
not require infectious PrPSc conformation.
Even though many studies argue that soluble A  oligomers
such as ADDLs are off ﬁbril formation pathways, they may
nonetheless share some structural similarity with protoﬁbrils.
An NMR study of the intermediates of globulomer formation,
the so-called preglobulomer, suggested parallel in register
 -sheets in the C-terminal region, even though the N-terminal
region has different conformation.275
Overall, the observations described above lead to the
conclusion that the inherent polymorphic nature of A 
assemblies can be associated with different toxic behavior.
Consequently, there is a need to delineate the structural
variability underlying the formation and stabilities of soluble
A  oligomers.
8. The Energy Landscape of Amyloidogenic
Proteins and Their Assemblies Is Rugged
The native-like states of amyloidogenic proteins are unstable
in environments favoring aggregation, leading to a broad
conformational heterogeneity. Among the native-like states,
some display amyloid-favored populations. While these con-
formations may have higher-energy and consequently exist at
low concentrations, they may be complementary to a ﬁbrilar
state surface. These binding-favored conformers would associate
via the “conformational selection” mechanism. Binding stabi-
lizes these conformations, and shifts the population of the
monomers toward these binding-favored conformers, propagat-
ing the binding reaction.57,58,176,177,276-280 The larger are the
aggregates, the more stable are the associations (Figure 10).
Amyloid formation follows the conformational selection and
population shift mechanism now accepted as a general
paradigm in molecular recognition.56 This view is based on
a dynamic energy landscape picture of protein folding and
protein binding. The kinetics of the amyloid formation
process depends on the relative stabilities of the states, and
the barrier heights that need to be crossed in the conforma-
tional transitions, which are the outcome of environmental
conditions.
Protein conformations and their associations have been
optimized by evolution toward speciﬁc biological functions.
Thus, it is expected that certain states are favored over others
due to (some) energy gaps between the favored and the less-
favored states; this, however, is not the case in amyloid
formation, which is a misfolded, diseased state presenting a
rugged energy landscape. Because the toxic non-native
amyloidogenic conformations are not under selection pressure
to preferentially assemble into a speciﬁc oligomer, the
outcome is an extensive polymorphic range. As the hetero-
geneous seeds and ﬁbrils grow, the ordered polymorphic
aggregates will increasingly stabilize. Metal ions, such as
Figure 10. Polymerization of A  peptides involves continuous
hierarchical redistributions of the polymorphic ensembles on a
rugged energy landscape. For illustration, we present ﬁve aggrega-
tion phases starting from the native states and ending in the ﬁbril
forms. The arrow on the left indicates the evolution of the
aggregated states with time: (A) The conformational ensemble of
the “normal” folded monomers (three schematic ﬁgures in the
middle) and partially disordered or unfolded states (the right and
the left schematic ﬁgures). (B) Under certain conditions, folded
monomers assemble toward polymorphic seeds or partially ag-
gregated states (green, blue, and yellow boxes), redistributing the
conformational ensemble. The native disordered or unfolded states
(red schematic ﬁgures) may still have a large population. (C)
“Critical intermediates” may be different partially aggregate states
(green, blue, and yellow boxes) and very early stage of small
oligomers (two right schematic ﬁgures). (D) Certain “critical
intermediates” can lead to both different amyloid seeds (three left
schematic ﬁgures) and different soluble ADDL-like oligomers
(orange balls). The soluble ADDL-like oligomers are prior to
amyloidogenic protoﬁbril formation. Polymorphic seeds and poly-
morphic soluble oligomers present different toxic mechanisms
(discussed in section 7). (E) The different ﬁbril forms are the most
stable states of the A  peptide amyloid: protoﬁlament fragments
(blue), protoﬁbril forms (yellow and green), and mature ﬁbril (left
schematic ﬁgure).
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further complicate these scenarios. Each A  conformer can
coordinate metal ions via different residues; because the
differences in the stabilities may be not large, the complexity
of the landscape, which reﬂects the polymorphic range, vastly
increases.
The nature of the rugged energy landscape of amy-
loidogenic peptides provides a conceptual framework for
polymorphic stages in protein aggregation. As shown in
Figure 10, we may describe ﬁve protein aggregation phases,
with hierarchical redistribution of the ensembles. The
“normal” folded stage (Figure 10A) and partially unfolded
or aggregated state (Figure 10B) have been universally
regarded as necessary steps. However, where to position the
“soluble oligomers” with respect to the main ﬁbril forming
pathway is still unclear. Even though small amyloidogenic
oligomers are on the pathway to seed and larger protoﬁbril
formation, ADDL-like species were suggested to be off
pathway (for example, as depicted by Roychaudhuri et al.281).
Such view overlooks common features of ADDLs and other
 -sheet-rich polymer forms.275 Here, we call attention to the
possible existence of certain “critical intermediates” (Figure
10C), which can lead to both seeds and other soluble ADDL-
like oligomers (Figure 10D). From this point of view, all
soluble oligomers are polymorphic forms distributed on the
energy landscape prior to (proto-)ﬁbril formation (Figure
10E). Thus, in principle, a drug can inhibit such critical
intermediates, preventing seed and other ADDL-like oligo-
mer formation.
Conformational selection and population shift is the key
mechanism in biomolecular recognition,56 and adding mono-
mers and small oligomers to amyloid seeds in ﬁbril growth177
is a molecular recognition event.54 Within such general
framework, the “dock and lock” mechanism for the deposi-
tion of soluble A  onto amyloid was proposed to be mediated
by two distinct kinetic processes. In the ﬁrst “dock” phase,
the addition of A  to the amyloid seeds can be reversible,
while in the second “lock” phase, the deposited peptide
becomes irreversibly associated with the template in a time-
dependent manner.282 In particular, in 2001 Massi and Straub
combined the “dock-lock” mechanism with the energy
landscape to explain the A  amyloid growth,283 thus unifying
a number of schemes proposed to describe ﬁbril elongation,
is in good agreement with experimental observations for A 
amyloid283 and prion growth.284
Extensive molecular dynamics simulations of A 16-22 in
water88 and urea285 indicated that both hydrophobic interac-
tions and backbone hydrogen bonds are important for A 16-22
oligomer stability. The kinetics of dissociation of the A 16-22
oligomer286 and oligomer growth287 both involve dock and
lock stages. Importantly, it was found that the mobile
structured oligomers undergo large conformational changes
to accommodate the added monomer, a clear indication of
mutual conformation selection process.287
Simulation of ﬁbril growth of other fragments, A 35-40
(MVGGVV),288 A 10-40,289 and A 10-40 with an Asp23Tyr
mutation,290 pointed to a two-stage mechanism.282,283 The
simulations of A 10-40 emphasize that the docking transition
appears to be continuous and it occurs without free energy
barriers or intermediates. Still, it should be distinguished here
between short peptides and proteins, short peptides being
random coil in solution. During the docking transition,
incoming A  monomers are disordered on the ﬁbril edge.
The locking stage is characterized by the rugged free energy
landscape. The locking step takes place when an incoming
A  peptide forms a parallel  -sheet structure on the ﬁbril
edge. Because the  -sheets formed by locked A  peptides
are typically off-register, the structure of the locked phase
differs from the structure of the ﬁbril interior.289 Polymorphic
forms can also derive from a variation of pre-existing seeds.
Finally, docking291-293 and the role of conformational
ensembles in docking associations56 are general paradigm
in protein and biomolecular recognition.
9. Conclusions
Experimental and computational studies of A  amyloids
suggest that for any given segment there are one or more
preferred parallel and (or) antiparallel structural states. The
preferred organizations of the A  fragments do not appear
to present straightforward “rules” with respect to length,
hydrophobicity, charge, etc. Because polymorphism is pre-
sented by different A  segments, clearly a combination of
these segments would lead to polymorphic full-length A ,
although the relative populations in the full sequence are
likely to be different. This leads us to argue that the observed
polymorphism for the disease-related species derives from
combinations of the preferred fragment architectures. Because
these are strongly affected by the environment, the trade-
off among these fragment-interactions and the key nucleation
sites may determine the polymorphic oligomer (and ﬁbril)
outcome, particularly with respect to parallel/antiparallel
backbone alignments.
How the A  peptides assemble and form toxic entities
and what is the mechanism of toxicity are major questions
that persist in Alzheimer research. To address such
questions, it is essential to have working structural models
of small A  oligomers. Two types of models of the three-
dimensional structures of A  oligomers have been reported
from computational and experimental studies. The ﬁrst is
the Ma-Nussinov-Tycko model,46,68 and the second is
by Lu ¨hrs et al.,15 indicating polymorphism derived from
different turn structures. Additional amyloid organizational
motifs containing a U-turn have been reported.150,191,192
Architectures for the same sequence, which include such a
U-turn in their structure, and have similar parallel organiza-
tion, may be different, due to different turn conformations.
The resulting side-chain packing can affect the left-handed
twist along the main axis of the amyloid ﬁbril, leading to
different ﬁbril morphologies. Nonetheless, it is important to
bear in mind that these may only present the prevailing
organizations under the experimental conditions; subpopu-
lations with different morphologies may not be captured. The
further association of the oligomeric forms leads to combi-
natorial increase of polymorphic populations at the supramo-
lecular and matured ﬁbril levels. Polymorphism can also be
demonstrated by metal ion binding to A  oligomers. Because
metal ions can coordinate with different residues in each
structural model, the variety of the morphologies can increase
dramatically.
It behooves us to emphasize, however, that here we review
polymorphism focusing on larger scale ﬁbril organization.
We do not discuss polymorphism as relating to small side-
chain conformational variability and its effects on the
aggregated states. This is because current experimental data,
based on ssNMR, cryo-EM, ﬁber diffraction, and mutational
studies, are unable to provide such high resolution detail.
We further only touched on the effects of pathways and
intermediate states because experimental data are scant.
Polymorphism in Alzheimer A  Amyloid Organization Chemical Reviews, 2010, Vol. 110, No. 8 4833Different pathways can lead to different preferred confor-
mational states; however, pathways are strongly dependent
on conditions, for example, concentration, sequence effects,
pH, and temperature.121,294-298 Our focus on A -derived
peptides may miss structural contributions like hydrogen-
bond ladders, as, for example, for in-parallel stacked Asn or
Gln, which also greatly enhances the stability of a parallel
orientation.186
Nevertheless, the A -derived peptides provide an excellent
example toward the understanding of amyloid polymorphism.
While here we highlighted hydrophobic interactions as
contributing to an increase in polymorphic amyloid behavior,
electrostatic interactions could decrease the variability, and
steric zipper (vdW) effects may increase or decrease poly-
morphism depending on the geometric match. Eventually,
for amyloid polymorphism, both dominant and minor forms
should all be treated in addressing the mechanism of
aggregation and toxicity, because it is always possible that
minor species are the toxic agents. Therefore, comprehension
of polymorphism should assist in therapeutic agents design.
Currently, it is increasingly recognized that amyloids
present a vast range of conformational states. Their energy
landscape is rugged. Complementary protein conformations
are selected from equilibrium of low-energy and higher-
energy conformations. This “selected-ﬁt”,280 or conforma-
tional selection mechanism,57,58,176,177,276-279 is based on a
dynamic energy-landscape picture of protein folding. The
polymorphic differences may or may not be large; polymor-
phism can be expressed in altered  -strands arrangements,
altered turn conformations, altered sheet-sheet registrations,
differences in the locations and fragment sizes of regions
that are disordered, different sheet organizations, and dif-
ferent supramolecular packing. Because these have not been
optimized by evolution for a particular function, the differ-
ences in stabilities between the states are likely to be small,
with the distribution of the populations easily shifting under
even slight changes in cellular conditions. Because amyloids
are involved in human disease, comprehension of the range
of (preferred) states on their own and when interacting with
metal ions is vital. Here, we addressed this challenging
problem, reviewing available data within this framework,
focusing on the A .
Polymorphism raises a key question: how to prevent AD
with drug design or other therapeutic approaches. Targeting
toxicity in late stage AD may miss the reservoir of poly-
morphic forms; preventing A  production may encounter
side effects derived from normal A  function loss. If
common links among polymorphic forms can be established,
then targeting the bottleneck would be more effective. The
“critical intermediates” (for example, as in Figure 10C) could
be the main AD targets.
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11. Note Added in Proof
Since the completion of this review, the polymorphic states
of A  oligomers coordinated with Zn2+, using the experi-
mental data cited in this review in Section 6 and in Figure
9, were described in Miller et al. See ref. 299.
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